
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6483813/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	People living with undiagnosed HIV infection and a low CD4 count: estimates from surveillance data, Italy, 2012 to 2014. Eurosurveillance, 2018, 23, .	3.9	2
2	Higher rates of tripleâ€class virological failure in perinatally <scp>HIV</scp> â€infected teenagers compared with heterosexually infected young adults in Europe. HIV Medicine, 2017, 18, 171-180.	1.0	45
3	Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients. Annals of Internal Medicine, 2017, 166, 9.	2.0	41
4	Reference curves for <scp>CD</scp> 4 Tâ€cell count response to combination antiretroviral therapy in <scp>HIV</scp> â€lâ€infected treatmentâ€naÃ⁻ve patients. HIV Medicine, 2017, 18, 33-44.	1.0	16
5	Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers. PLoS ONE, 2017, 12, e0173893.	1.1	30
6	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. Clinical Infectious Diseases, 2016, 63, ciw519.	2.9	20
7	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. Journal of Antimicrobial Chemotherapy, 2016, 71, 1352-1360.	1.3	4
8	Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?. Aids, 2015, 29, 2323-2333.	1.0	21
9	Estimating Minimum Adult HIV Prevalence: A Cross-Sectional Study to Assess the Characteristics of People Living with HIV in Italy. AIDS Research and Human Retroviruses, 2015, 31, 282-287.	0.5	16
10	Mortality in migrants living with HIV in western Europe (1997–2013): a collaborative cohort study. Lancet HIV,the, 2015, 2, e540-e549.	2.1	19
11	Factors associated with short-term changes in HIV viral load and CD4+ cell count in antiretroviral-naive individuals. Aids, 2014, 28, 1351-1356.	1.0	32
12	Delayed HIV diagnosis and initiation of antiretroviral therapy. Aids, 2014, 28, 2297-2306.	1.0	39
13	Evaluation of Rapid Progressors in HIV Infection as an Extreme Phenotype. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 15-21.	0.9	16
14	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Clinical Infectious Diseases, 2014, 58, 1312-1321.	2.9	140
15	Effect of HCV Infection on Cause-Specific Mortality After HIV Seroconversion, Before and After 1997. Gastroenterology, 2013, 144, 751-760.e2.	0.6	76
16	Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Medicine, 2013, 10, e1001510.	3.9	256
17	Predictors of CD4+ T-Cell Counts of HIV Type 1–Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. Journal of Infectious Diseases, 2013, 207, 759-767.	1.9	7
18	The Incidence of AIDS-Defining Illnesses at a Current CD4 Count ≥200 Cells/µL in the Post–Combination Antiretroviral Therapy Era. Clinical Infectious Diseases, 2013, 57, 1038-1047.	2.9	92

#	Article	IF	CITATIONS
19	Impact of HIV-1 Subtype on CD4 Count at HIV Seroconversion, Rate of Decline, and Viral Load Set Point in European Seroconverter Cohorts. Clinical Infectious Diseases, 2013, 56, 888-897.	2.9	88
20	All-cause mortality in treated HIV-infected adults with CD4 >=500/mm3 compared with the general population: evidence from a large European observational cohort collaborationA. International Journal of Epidemiology, 2012, 41, 433-445.	0.9	217
21	Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infectious Diseases, The, 2012, 12, 119-127.	4.6	41
22	Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 294-299.	0.9	13
23	Targeting Candidates for Directly Administered Highly Active Antiretroviral Therapy: Benefits Observed in HIV-Infected Injecting Drug Users in Residential Drug-Rehabilitation Facilities. AIDS Patient Care and STDs, 2011, 25, 359-364.	1.1	6
24	The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. Aids, 2011, 25, 1083-1091.	1.0	120
25	Decline of CD4+ T-cell count before start of therapy and immunological response to treatment in antiretroviral-naive individuals. Aids, 2011, 25, 1041-1049.	1.0	14
26	Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years. Archives of Internal Medicine, 2010, 170, 410-419.	4.3	42
27	Immunologic Response to Highly Active Antiretroviral Therapy and Mortality Reduction in a Cohort of Human Immunodeficiency Virus–Positive Persons in Mozambique. American Journal of Tropical Medicine and Hygiene, 2010, 83, 1128-1132.	0.6	8
28	Pretreatment CD4 Cell Slope and Progression to AIDS or Death in HIV-Infected Patients Initiating Antiretroviral Therapy—The CASCADE Collaboration: A Collaboration of 23 Cohort Studies. PLoS Medicine, 2010, 7, e1000239.	3.9	54
29	Has Human Immunodeficiency Virus Become More Virulent?. Clinical Infectious Diseases, 2009, 48, 1293-1295.	2.9	1
30	Viral causes of influenzaâ€like illness: Insight from a study during the winters 2004–2007. Journal of Medical Virology, 2009, 81, 2066-2071.	2.5	32
31	Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. Aids, 2009, 23, 1743-1753.	1.0	200
32	Changes in the incidence and predictors of human immunodeficiency virus–associated dementia in the era of highly active antiretroviral therapy. Annals of Neurology, 2008, 63, 213-221.	2.8	167
33	Epidemiological investigation of a varicella outbreak in an Italian prison. Scandinavian Journal of Infectious Diseases, 2008, 40, 943-945.	1.5	23
34	Temporal Trends in Postseroconversion CD4 Cell Count and HIV Load: The Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985–2002. Journal of Infectious Diseases, 2007, 195, 525-534.	1.9	44
35	An outbreak of HIV-1 subtype G among Italian injecting drug users. Aids, 2007, 21, 1213-1215.	1.0	21
36	Homologous intrauterine insemination in controlled ovarian hyperstimulation cycles: A comparison among three different regimens. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2006, 129, 155-161.	0.5	20

#	Article	IF	CITATIONS
37	Kaposi's Sarcoma in Transplant and HIV-infected Patients: An Epidemiologic Study in Italy and France. Transplantation, 2005, 80, 1699-1704.	0.5	50
38	Temporal Trend in the Level of 90K Glycoprotein after HIV Seroconversion among Persons Coinfected with Hepatitis C Virus. Infection, 2005, 33, 101-102.	2.3	3
39	The Presence of Antiâ€Tat Antibodies Is Predictive of Longâ€Term Nonprogression to AIDS or Severe Immunodeficiency: Findings in a Cohort of HIVâ€1 Seroconverters. Journal of Infectious Diseases, 2005, 191, 1321-1324.	1.9	118
40	Increased HIV incidence among men who have sex with men in Rome. Aids, 2005, 19, 1429-1431.	1.0	27
41	Combined antiretroviral therapy and the incidence of acquired immunodeficiency syndrome-related central nervous system diseases. Annals of Neurology, 2004, 56, 307-307.	2.8	0
42	The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy. Aids, 2004, 18, 2313-2318.	1.0	29
43	The effect of aging on the incidence of Kaposi's sarcoma among HIV-positive individuals with known dates of seroconversion. International Journal of Cancer, 2003, 104, 251-254.	2.3	7
44	Effect of multiple herpesvirus infections on the progression of HIV disease in a cohort of HIV seroconverters. Journal of Medical Virology, 2003, 69, 182-187.	2.5	9
45	Effect of Maternal HIV and Malaria Infection on Pregnancy and Perinatal Outcome in Zimbabwe. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 289-294.	0.9	94
46	Prevalence and Determinants of Herpes Simplex Virus Type 2 Infection in a Cohort of HIV-Positive Individuals in Italy. Sexually Transmitted Diseases, 2002, 29, 665-667.	0.8	12
47	No Protective Effect of Acyclovir on HIV Disease Progression in a Cohort of Hsv-2–HIV-Infected Individuals. Antiviral Therapy, 2002, 7, 289-291.	0.6	7
48	Absence of an effect of herpes simplex virus type 2 infection on HIV disease progression: data from a cohort of HIV-positive individuals with known date of seroconversion. Aids, 2001, 15, 133-135.	1.0	11
49	Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens. Aids, 2001, 15, 1733-1736.	1.0	35
50	Incidence of Invasive Cervical Cancer in a Cohort of HIV-Seropositive Women Before and After the Introduction of Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 377-380.	0.9	12
51	Incidence of Invasive Cervical Cancer in a Cohort of HIV-Seropositive Women Before and After the Introduction of Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 377-380.	0.9	34
52	Cancer risk among men with, or at risk of, HIV infection in southern Europe. Aids, 2000, 14, 553-559.	1.0	105
53	Incidence of Kaposi's sarcoma and HHV-8 seroprevalence among homosexual men with known dates of HIV seroconversion. Aids, 2000, 14, 1647-1653.	1.0	28
54	Longitudinal Human Immunodeficiency Virus Type 1 Load in the Italian Seroconversion Study: Correlates and Temporal Trends of Virus Load. Journal of Infectious Diseases, 1999, 180, 1018-1024.	1.9	66

#	Article	IF	CITATIONS
55	Serum IgG antibodies to human herpesvirus-6 (HHV-6) do not predict the progression of HIV disease to AIDS. Italian Seroconversion Study group. European Journal of Epidemiology, 1999, 15, 317-322.	2.5	5
56	Risk of invasive cervical cancer among women with, or at risk for, HIV infection. , 1999, 82, 334-337.		90
57	Temporal Changes in the Rate of Progression to Death Among Italians With Known Date of HIV Seroconversion: Estimates of the Population Effect of Treatment. Journal of Acquired Immune Deficiency Syndromes, 1999, 22, 65.	0.3	39
58	Risk of invasive cervical cancer among women with, or at risk for, HIV infection. International Journal of Cancer, 1999, 82, 334-337.	2.3	1
59	Frequency and determinants of use of antiretroviral and prophylactic therapies against Pneumocystis carinii Pneumonia (PCP) before AIDS diagnosis in Italy. European Journal of Epidemiology, 1998, 14, 41-47.	2.5	7
60	The rate of CD4 decline as a determinant of progression to AIDS independent of the most recent CD4 count. Epidemiology and Infection, 1998, 121, 369-376.	1.0	14
61	Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. Aids, 1997, 11, 461-467.	1.0	17
62	Cancer incidence in a cohort of human immunodeficiency virus seroconverters. , 1997, 79, 1004-1008.		73
63	How Many HIV-Infected Individuals May Be Defined as Long-term Nonprogressors? A Report from the Italian Seroconversion Study. Journal of Acquired Immune Deficiency Syndromes, 1997, 14, 243-248.	0.3	31
64	Category of exposure to HIV and age in the progression to AIDS: longitudinal study of 1199 people with known dates of seroconversion. BMJ: British Medical Journal, 1996, 313, 583-586.	2.4	88
65	Clinical characteristics and prognostic value of acute retroviral syndrome among injecting drug users. Aids, 1995, 9, 597-604.	1.0	49
66	Evaluation of symptoms suggestive of HIV acute disease among injecting drug users. Journal of Infection, 1995, 30, 263-264.	1.7	1
67	Coinfection of Hepatitis C Virus with Human Immunodeficiency Virus and Progression to AIDS. Journal of Infectious Diseases, 1995, 172, 1503-1508.	1.9	158
68	HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. BMJ: British Medical Journal, 1994, 309, 1537-1542.	2.4	88
69	Declining prevalence of HIV infection among injecting drug users entering drug treatment in Italy: 1990–1991. European Journal of Epidemiology, 1993, 9, 663-666.	2.5	11
70	Estimating the trend of the epidemic of drug use in Italy, 1985-89. Addiction, 1992, 87, 1643-1648.	1.7	12